Skip to main content
Gastroenterology Research and Practice logoLink to Gastroenterology Research and Practice
. 2020 Apr 1;2020:7419534. doi: 10.1155/2020/7419534

Erratum to “DAB2IP Downregulation Enhances the Proliferation and Metastasis of Human Gastric Cancer Cells by Derepressing the ERK1/2 Pathway”

Liang Sun 1, Yizhou Yao 1, Ting Lu 2, Zengfu Shang 3, Shenghua Zhan 4, Weiqiang Shi 4, Guofeng Pan 1, Xinguo Zhu 1, Songbing He 1,
PMCID: PMC7152946  PMID: 32328097

In the article titled “DAB2IP Downregulation Enhances the Proliferation and Metastasis of Human Gastric Cancer Cells by Derepressing the ERK1/2 Pathway” [1], there was an error in Figure 2, where the Western blots in Figures 2(b) and 2(c) were duplicated, due to a production error. The correct figure is as follows.

Figure 1.

Figure 1

Expression of DAB2IP in human gastric cancer cells and the knockdown efficiency of DAB2IP. (a) DAB2IP protein and mRNA expression in four gastric cancer cell lines were detected by Western blot and QRT-PCR. The bar graphs represent the 18 s-normalized DAB2IP mRNA levels. Error bars represent SEM (n = 3). (b, c) The protein and mRNA levels of DAB2IP expression in wild-type cells (shControl) and in cells with stable knockdown of DAB2IP (shDAB2IP) were tested by Western blot and QRT-PCR in (b) AGS and (c) SGC7901 gastric cancer cells. Error bars represent SEM (n = 3). Statistical significance was determined by a two-tailed, unpaired Student's t-test. ∗∗P < 0.01.

References

  • 1.Sun L., Yao Y., Lu T., et al. DAB2IP downregulation enhances the proliferation and metastasis of human gastric cancer cells by derepressing the ERK1/2 pathway. Gastroenterology Research and Practice. 2018;2018:10. doi: 10.1155/2018/2968252.2968252 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gastroenterology Research and Practice are provided here courtesy of Wiley

RESOURCES